|1.||Luijckx, Gert-Jan: 3 articles (08/2012 - 06/2007)|
|2.||Uyttenboogaart, Maarten: 3 articles (08/2012 - 06/2007)|
|3.||De Keyser, Jacques: 2 articles (08/2011 - 06/2007)|
|4.||Warburton, Elizabeth: 2 articles (01/2011 - 01/2008)|
|5.||Alawneh, Josef A: 2 articles (01/2011 - 01/2008)|
|6.||Morris, Rhiannon S: 2 articles (01/2011 - 01/2008)|
|7.||Clatworthy, Philip L: 2 articles (01/2011 - 01/2008)|
|8.||Grotta, J: 2 articles (01/2001 - 11/2000)|
|9.||Kaste, M: 2 articles (01/2001 - 11/2000)|
|10.||Koudstaal, P J: 2 articles (11/2000 - 09/2000)|
01/01/2002 - "Lubeluzole, given in the acute phase of ischaemic stroke, is not associated with a significant reduction of death or dependency at the end of scheduled follow-up period but seems to be associated with a significant increase of heart-conduction disorders (Q-T prolonged >450 msec)."
05/01/1998 - "Treatment benefit was related to stroke severity, as determined by the Clinical Global Impression rating, that is a pronounced clinically significant reduction in mortality was noted in the lubeluzole-treated patients for whom stroke severity was mild to moderate, but not in those for whom it was severe. "
01/01/2001 - "A combination of thrombolysis and a neuroprotecting agent or a combination of two neuroprotecting agents have been effective in experimental stroke, but the only clinical study with combination therapy (rt-PA with or without lubeluzole) was terminated prematurely before the planned population was enrolled. "
11/01/2000 - "This study failed to show an efficacy of lubeluzole in the treatment of acute stroke. "
05/01/1998 - "This multicentre, double-blind, placebo-controlled trial was conducted to assess the safety and efficacy of lubeluzole in patients with an acute ischaemic stroke. "
|2.||Brain Ischemia (Cerebral Ischemia)
10/01/2003 - "Lubeluzole [S-4-(2-benzothiazolylmethylamino)-alpha-((3,4-difluorophenoxy)methyl)-1-piperidineethanol] reduces the severity of cerebral injury in animal models of brain ischemia. "
04/01/2002 - "The aim of the present study was to test the neuroprotective effect of the novel benzothiazol compound lubeluzole on neuronal cell damage in fetal sheep arising from global cerebral ischemia. "
10/01/2003 - "Here, we examined the effect of preischemic treatment with lubeluzole on the acquisition of a trace-conditioned eyeblink response after 6.5 min of global cerebral ischemia. "
10/01/2003 - "Lubeluzole and conditioned learning after cerebral ischemia."
04/01/2002 - "From these results, we conclude that pretreatment with lubeluzole fails to protect the brain of fetal sheep near term from injury after transient global cerebral ischemia. "
06/15/2001 - "The results indicate that lubeluzole may be effective in ameliorating ionic or osmotic stress in a range of pathological conditions involving the rise of extracellular K+, and also in decreasing the vulnerability to stress in rats with hepatic failure."
06/15/2001 - "Lubeluzole attenuates K(+)-evoked extracellular accumulation of taurine in the striatum of healthy rats and rats with hepatic failure."
02/01/1997 - "The present study examined whether lubeluzole, administered after global incomplete ischemia in rats, is capable of preserving the structural integrity of CA1 hippocampus. "
04/20/2001 - "Lubeluzole was given intravenously 90 min before the onset of ischemia. "
01/26/1998 - "Interestingly, the protective effect (reduction of the infarct volume in rats to 77% of control; P < 0.01) was also found when the lubeluzole treatment (2.5 mg/kg) was started 3 h after ischemia. "
01/26/1998 - "Lubeluzole protects hippocampal neurons from excitotoxicity in vitro and reduces brain damage caused by ischemia."
06/01/1996 - "Lubeluzole, started 15 min after the onset of ischemia, had no adverse physiological or behavioral effects and reduce maximal infarct volume produced by 120 min or more of arterial occlusion by approximately 50%, from 143.2 +/- 11.8 mm3 (p < 0.05). "
|5.||Brain Injuries (Brain Injury)
10/01/1998 - "In Europe two promising studies have been stopped or shelved (Lubeluzole, Janssen-Cilag and BAYx3702, Bayer) and the future of pharmacological neuroprotection after traumatic brain injury is in doubt. "
07/01/1999 - "Under these experimental conditions, lubeluzole fails to exert beneficial effects following experimental traumatic brain injury (TBI)."
07/01/1999 - "Lubeluzole following traumatic brain injury in the rat."
07/01/1999 - "The present study investigated the effect of lubeluzole on contusion volume and brain edema following traumatic brain injury. "
|1.||Glutamic Acid (Glutamate)
|3.||Nitric Oxide Synthase (NO Synthase)
|4.||Nitric Oxide (Nitrogen Monoxide)
|5.||Insulin-Like Growth Factor Binding Protein 3
|6.||Tissue Plasminogen Activator (Alteplase)
|7.||Ion Channels (Ion Channel)
|8.||Insulin-Like Growth Factor I (IGF-1)
|10.||Aspirin (Acetylsalicylic Acid)